Sunesis Pharmaceuticals Announces Regulatory Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
July 24, 2015 9:14 AM EDTCantor Fitzgerald downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Hold with a price target of $2.00 (from $4.00).
Analyst Mara Goldstein commented, "We are downgrading shares of Sunesis to HOLD from BUY based on the disappointing FDA guidance that will require... More
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell, $1 PT
July 24, 2015 7:32 AM EDTRoth Capital downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Sell with a price target of $1.00 (from $5.50).
Analyst Joseph Pantginis commented, "Sunesis provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, though we believe the... More
Sunesis Pharmaceuticals (SNSS) Issues Update on Meetings with EMA, FDA Over Vosaroxin in AML
July 23, 2015 4:22 PM EDTSunesis Pharmaceuticals (NASDAQ: SNSS) announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States.
With respect to Europe, the company recently met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guide the company through the Marketing Authorization Application (MAA) process. Based on these substantive discussions, the company was encouraged to proceed with an MAA... More
